Bayer, Bicycle Therapeutics Partner to Develop Radiopharmaceuticals
Bayer will handle clinical development, manufacturing, and commercialization of radiopharmaceuticals discovered using Bicycle's platform.
Bayer, Telix Pharmaceuticals Partner to Study Nubeqa in Hormone-Sensitive Prostate Cancer
Telix will supply its PSMA imaging agent Illuccix, which Bayer will use to determine if patients have at least one PSMA-positive prostate cancer lesion at baseline.
Function Oncology Launches With $28M, Seeks to Transform Precision Cancer Therapy With CRISPR
The firm unveiled early validation data for its CRISPR-based functional genomics platform, which it hopes to commercialize as another tool doctors can use to individualize cancer care.
Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer
The firm will enroll patients to the Phase III clinical trial if they have a positive PSMA PET scan and their PSA score doubles within a year.
Ratio Therapeutics Raises $20M in Series A Financing
The firm, which launched last year with $20 million in seed funding, plans to use the money to develop targeted radiopharmaceuticals for patients with solid tumors.